FDA warns of rare skin reaction from Celgene's Revlimid

09/19/2008 | Wall Street Journal, The

Celgene's Revlimid, a treatment for blood cancer, may have caused 14 cases of Stevens-Johnson syndrome, a rare but serious skin reaction also known as toxic epidermal necrolysis, the FDA said on its Web site. The finding is based on the agency's postmarketing safety review of Revlimid, which was approved in December 2005.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI